RecruitingPhase 2NCT07441993
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Studying MALT lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Principal Investigator
- Shuhua yiHematology Hospital, Chinese Academy of Medical Sciences
- Intervention
- Orelabrutinib(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2028
Study locations (14)
- Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
- Xiangyang Central Hospital, Xiangyang, Hubei, China
- The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
- Jiangsu Province People's Hospital, Nanjing, Jiangsu, China
- Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
- The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
- The First Bethune Hospital of Jilin University, Changchun, Jilin, China
- Qilu Hospital of Shandong University, Jinan, Shandong, China
- Shandong Cancer Hospital & Institute, Jinan, Shandong, China
- Shandong Provincial Hospital, Jinan, Shandong, China
- Beijing Tongren Hospital, Capital Medical University, Beijing, China
- Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, China
Collaborators
Beijing Tongren Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07441993 on ClinicalTrials.govOther trials for MALT lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06510309Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaGottfried von Keudell, MD PhD
- RECRUITINGPHASE2NCT07372365Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.The First Affiliated Hospital of Soochow University
- RECRUITINGNCT06712459Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone LymphomaInternational Extranodal Lymphoma Study Group (IELSG)
- RECRUITINGPHASE2NCT06796998Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)Izidore Lossos, MD
- ACTIVE NOT RECRUITINGPHASE2NCT07480863Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ACTIVE NOT RECRUITINGPHASE2NCT07247383Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE2NCT07208981Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZLThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE2NCT06792825HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLMasonic Cancer Center, University of Minnesota